Clinical Trials Directory

Trials / Completed

CompletedNCT05174026

18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery

A Pilot Study on the Efficacy of Advanced 18F-FDG PET-MRI in Spine Stereotactic Radiosurgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This trial studies how well 18F-FDG PET-MRI works for treatment planning in patients with spine tumors. Diagnostic procedures, such as 18F-FDG PET-MRI may help radiation oncologists plan the best treatment for spine tumors, as well as help in follow-up after radiation therapy.

Detailed description

PRIMARY OBJECTIVES: I. Determine the therapeutic efficacy of fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)-magnetic resonance imaging (MRI) in spine stereotactic radiosurgery (SSRS) treatment planning compared to advanced MRI (aMRI) and conventional MRI (cMRI). II. Determine the diagnostic accuracy of 18F-FDG PET-MRI in follow-up of patients treated with SSRS. SECONDARY OBJECTIVES: I. Analysis of the subset of patients who eventually suffer local treatment failure to determine patterns of failure and potential predictive PET/MRI features at baseline. II. Analysis of the subset of patients who suffer complications of SSRS (e.g., vertebral compression fracture) to determine potential predictive imaging features. OUTLINE: Patients receive fludeoxyglucose F-18 intravenously (IV) over 1 minute, and then undergo PET-MRI over 1 hour, 30 days before radiation therapy, and 3 and 6 months after radiation therapy.

Conditions

Interventions

TypeNameDescription
OTHERFludeoxyglucose F-18Given IV
PROCEDUREMagnetic Resonance ImagingUndergo 18F-FDG PET-MRI
PROCEDUREPositron Emission TomographyUndergo 18F-FDG PET-MRI

Timeline

Start date
2018-11-30
Primary completion
2024-06-20
Completion
2024-06-20
First posted
2021-12-30
Last updated
2024-06-25

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05174026. Inclusion in this directory is not an endorsement.